Ernie Yulyaningsih, PhD, is a neuroscientist with more than 18 years of combined academic and industry experience. At NICO Therapeutics, she leads the translational sciences team that is responsible for developing and executing preclinical strategies. Her work integrates studies of the central nervous system with preclinical models to translate basic neuroscience findings into clinically relevant outcomes, such as identifying translatable biomarkers for pathway engagement, demonstrating proof-of-concept efficacy, and establishing the pharmacodynamic profiles that enable clinical dose projection. Prior to NICO Therapeutics, Dr. Yulyaningsih served as a lead for small molecule programs in Denali Therapeutics, including DNL343 (currently in Phase 2/3 trials for Amyotrophic Lateral Sclerosis), for which she authored or coauthored several clinical documents and peer-reviewed publications. Dr. Yulyaningsih obtained her PhD in neuroscience from the University of New South Wales, Sydney, and she completed her postdoctoral training at the University of California, San Francisco.